Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs. In addition, the company offers generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, and antiretrovirals medications, as well as over-the-counter products. The company was founded in 1983 and is headquartered in Mumbai, India.
Metrics to compare | SUN | Peers Peers - average of corresponding metrics from companies closely matching SUN: TORNTPHARM, PFIZER, CIPLA, ABBOTINDIA, MOREPENLAB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSUNPeersSector |
---|---|---|---|---|
P/E Ratio | 39.4x | 35.8x | −0.6x | |
PEG Ratio | 1.34 | 1.03 | 0.00 | |
Price/Book | 6.3x | 6.2x | 2.6x | |
Price / LTM Sales | 8.7x | 7.4x | 3.2x | |
Upside (Analyst Target) | 14.8% | 10.4% | 40.6% | |
Fair Value Upside | Unlock | −12.2% | 7.1% | Unlock |